Alterity Therapeutics (NASDAQ:ATHE) Upgraded at Zacks Research
Zacks Research upgraded shares of Alterity Therapeutics (NASDAQ:ATHE – Free Report) to a hold rating in a research note published on Thursday,Zacks.com reports. Other research analysts have also recently issued research reports about the stock. Canaccord Genuity Group assumed coverage on shares of Alterity Therapeutics in a research report on Wednesday, December 17th. They issued [...]




